Kyverna Therapeutics Inc
KYTX
Company Profile
Business description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Contact
5980 Horton Street
Suite 550
EmeryvilleCA94608
USAT: +1 510 925-2492
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
119
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,422.80 | 23.00 | 0.27% |
| CAC 40 | 7,626.84 | 70.08 | -0.91% |
| DAX 40 | 23,115.96 | 133.69 | -0.58% |
| Dow JONES (US) | 41,113.97 | 284.97 | 0.70% |
| FTSE 100 | 8,559.33 | 38.09 | -0.44% |
| HKSE | 22,853.42 | 161.54 | 0.71% |
| NASDAQ | 17,738.16 | 48.50 | 0.27% |
| Nikkei 225 | 36,950.14 | 170.48 | 0.46% |
| NZX 50 Index | 12,467.03 | 29.86 | -0.24% |
| S&P 500 | 5,631.28 | 24.37 | 0.43% |
| S&P/ASX 200 | 8,193.00 | 14.70 | 0.18% |
| SSE Composite Index | 3,352.82 | 10.15 | 0.30% |